Shandong Boan Biotechnology Co (HKG:6955) said its investigational new drug application for BA1203 has been accepted by China's Center for Drug Evaluation of the National Medical Products Administration.
Shares of the biotechnology company fell 5% in recent trade.
BA1203 is an immuno-oncology therapy candidate developed to treat multiple solid tumors, according to a Hong Kong bourse filing on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.